Elan Grants Full Tysabri Rights To Biogen

Elan Corp. (NYSE: ELN) swung to a profit for the fourth quarter but the company announced a restructuring of its Tysabri agreement granting full rights of the drug to Biogen (Nasdaq: BIIB). Shares of Elan fell 97 cents to $9.49 while Biogen stock leaped $4.51 to $161.87.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here